• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Diagnostic tools
      • Research team
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

Anja Bauerfeind

Director, Statistics and Methodology

Anja Bauerfeind, Director of Statistics and Methodology, oversees the design and innovative development of ZEG Berlin’s study methodology and serves as a statistical consultant for external projects. Her input is invaluable on sample size calculations, statistical analysis plans, hypothesis testing and modeling.

Anja studied mathematics at the University of Applied Science in Berlin, and received her PhD from the Charité Berlin in 2007 in cooperation with MDC (Max Delbrück Center for Molecular Medicine), Berlin, Department of Bioinformatics.  She completed her postdoctoral research at MDC, Department of Genetics and Genomics of Cardiovascular Diseases, analyzing high-dimensional genetic data in complex traits by the application of generalized linear models and network analysis.

  • share 
  • tweet 
  • share 
  • share 

Publications

Boehnke Tanja, Eggebrecht Lisa, Viet Mareike, Heinemann Klaas, Bauerfeind Anja, How did regional lockdowns during the COVID-19 pandemic affect recruitment into a large multinational cohort study of intrauterine device users? Contraception. 2023; 10.1016/j.contraception.2023.110003.
Barnett Clare, Bauerfeind Anja, von Stockum Sophia, Heinemann Klaas, Thromboembolic safety of norethisterone vs levonorgestrel in combined oral contraceptive users: a pooled analysis of 4 large prospective cohort studies AJOG Global Report. 2022; 10.1016/j.xagr.2021.100041.
Boehnke Tanja, Bauerfeind Anja, Hagemann Christine, Lange Jens A., Heinemann Klaas, Intrauterine device prescribing patterns and types in Europe – a cross-sectional analysis of the European Active Surveillance LCS12 Study. European Gynecology & Obstetrics. 2022; 29–40. 10.53260/EGO.224015 .
Download PDF: Boehnke-et-al.-2022_IUD-prescribing-patterns-and-types-in-Europe_LCS12.pdf
Donders Gilbert, Kopp Kallner Helena , Hauck Brian, Bauerfeind Anja, Frenz Ann-Kathrin, Zvolanek Michal, Stovall Dale W., Bleeding profile satisfaction and pain and ease of placement with levonorgestrel 19.5 mg IUD: findings from the Kyleena® Satisfaction study The European Journal of Contraception & Reproductive Health Care. 2022; 10.1080/13625187.2022.2136939.
Barnett Clare, Bauerfeind Anja, von Stockum Sophia, Heinemann Klaas, Thromboembolic safety profile of low-dose estradiol (valerate) in combined hormonal preparations: Implications for the development of new hormonal endometriosis and uterine fibroid therapies Journal of Endometriosis and Pelvic Pain Disorders. 2021; 1 - 10. 10.1177/22840265211019546.
Reed Suzanne, Koro Carol, DiBello Julia, Becker Kerstin, Bauerfeind Anja, Franke Christian, Heinemann Klaas, Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism European Journal of Contraception & Reproductive Health Care. 2021; 1 - 8. 10.1080/13625187.2021.1987410 .
Reed Suzanne, Koro Carol, DiBello Julia, Becker Kerstin, Bauerfeind Anja, Franke Christian, Heinemann Klaas, Unintended pregnancy in users of nomegestrol acetate and 17β-oestradiol (NOMAC-E2) compared with levonorgestrel-containing combined oral contraceptives: final results from the PRO-E2 study European Journal of Contraception & Reproductive Health Care. 2021; 1-7. 10.1080/13625187.2021.1988923.
Barnett Clare, Bauerfeind Anja, von Stockum Sophia, Grimes David A., Heinemann Klaas, Comparing the Cardiovascular Risk of Norethindrone Acetate & Levonorgestrel Pills: Is There a Difference? [10I]. Obstetrics & Gynecology. 2020; Volume 135 - Issue - p 94S. 10.1097/01.AOG.0000664136.96902.7e.
Bauerfeind Anja, Do Minh Thai, Heinemann Klaas, The Influence of Women’s Educational Level on Unintended Pregnancy Rates amongst Users of Combined Oral Contraceptives Pharmacoepidemiology and Drug Safety. 2017; Volume 26, Issue Supplement S2 Pages 1–674.
Barnett Clare, Bauerfeind Anja, Do Minh Thai, Heinemann Klaas, Influence of age and BMI on risk of venous thromboembolism: a meta-analysis of 246,513 women using combined oral contraceptives based on 521,516 women-years. Pharmacoepidemiology and Drug Safety. 2016; Aug;25:(S3):3-680. 10.1002/pds.4070.
Bauerfeind Anja, Barnett Clare, Do Minh Thai, Heinemann Klaas, The effect of BMI on unintended pregnancy rates amongst users of combined oral contraceptives Pharmacoepidemiology and Drug Safety. 2016; Aug;25:(S3):3-680. 10.1002/pds.4070.
Esparza-Gordillo J, Matanovic A, Marenholz I, Bauerfeind Anja, et al , Maternal filaggrin mutations increase the risk of atopic dermatitis in children: an effect independent of mutation inheritance.. PLoS Genet. 2015; 11(3):e1005076. doi: 10.1371/journal.pgen.1005076.
Marenholz I, Esparza-Gordillo J, Rüschendorf F, Bauerfeind Anja, et al , Meta-analysis identifies seven susceptibility loci involved in the atopic march. Nat Commun. 2015; 6:8804. doi: 10.1038/ ncomms9804.
Günther C, Kind B, Reijns MA, Berndt N, Martinez-Bueno M, Wolf C, Tüngler V, Chara O, Lee YA, Hübner N, Bicknell L, Blum S, Krug C, Schmidt F, Kretschmer S, Koss S, Astell KR, Ramantani G, Bauerfeind Anja, et al , Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J Clin Invest. 2015; 125(1):413-24. doi:10.1172/JCI78001.
Paternoster L, Standl M, Waage J, Baurecht H, Hotze M, Strachan DP, Curtin JA, Bønnelykke K, Tian C, Takahashi A, Esparza-Gordillo J, Alves AC, Thyssen JP, den Dekker HT, Ferreira MA, Altmaier E, Sleiman PM, Xiao FL, Gonzalez JR, Marenholz I, Kalb B, Pino-Yanes M, Xu CJ, Carstensen L, Groen-Blokhuis MM, Venturini C, Pennell CE, Barton SJ, Levin AM, Curjuric I, Bustamante M, Kreiner-Møller E, Lockett GA, Bacelis J, Bunyavanich S, Myers RA, Matanovic A, Kumar A, Tung JY, Hirota T, Kubo M, McArdle WL, Henderson AJ, Kemp JP, Zheng J, Smith GD, Rüschendorf F, Bauerfeind Anja, et al , EArly Genetics and Lifecourse Epidemiology (EAGLE) Eczema Consortium. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet. 2015; 47(12):1449-56. doi: 10.1038/ng.3424.
Rintisch C, Heinig M, Bauerfeind Anja, et al , Natural variation of histone modification and its impact on gene expression in the rat genome. Genome Res. 2014; 24:942-53.
Rat Genome Sequencing and Mapping Consortium., Baud A, Hermsen R, Guryev V, Stridh P, Graham D, McBride MW, Foroud T, Calderari S, Diez M, Ockinger J, Beyeen AD, Gillett A, Abdelmagid N, Guerreiro-Cacais AO, Jagodic M, Tuncel J, Norin U, Beattie E, Huynh N, Miller WH, Koller DL, Alam I, Falak S, Osborne-Pellegrin M, Martinez-Membrives E, Canete T, Blazquez G, Vicens-Costa E, Mont-Cardona C, Diaz-Moran S, Tobena A, Hummel O, Zelenika D, Saar K, Patone G, Bauerfeind Anja, et al , Combined sequence-based and genetic mapping analysis of complex traits in outbred rats. Nat Genet. 2013; 45(7):767-75.
Esparza-Gordillo J, Schaarschmidt H, Liang L, Cookson W, Bauerfeind Anja, et al , A functional IL-6 receptor (IL6R) variant is a risk factor for persistent atopic dermatitis. J Allergy Clin Immunol. 2013; 132(2):371-7.
Caglayan S, , Bauerfeind Anja, et al , Identification of Alzheimer disease risk genotype that predicts efficiency of SORL1 expression in the brain. Arch Neurol. 2012; 69:373-9.
Knüppel S, Esparza-Gordillo J, Marenholz I, Holzhütter HG, , Bauerfeind Anja, et al , Multi-locus stepwise regression: a haplotype-based algorithm for finding genetic associations applied to atopic dermatitis. BMC Med Genet. 2012; 13:8. doi: 10.1186/1471-2350-13-8.
Marenholz I, Rivera VA, Esparza-Gordillo J, Bauerfeind Anja, et al , Association screening in the Epidermal Differentiation Complex (EDC) identifies an SPRR3 repeat number variant as a risk factor for eczema. J Invest Dermatol. 2011; 131:1644-9.
Marenholz I, Bauerfeind Anja, et al , The eczema risk variant on chromosome 11q13 (rs7927894) in the population-based ALSPAC co¬hort: a novel susceptibility factor for asthma and hay fever. Hum Mol Genet. 2011; 20:2443-9.
Heinig M, Petretto E, Wallace C, Bottolo L, Rotival M, Lu H, Li Y, Sarwar R, Langley SR, Bauerfeind Anja, et al , A trans-acting locus regulates an anti-viral expression network and type 1 diabetes risk. Nature. 2010; 467:460-4.
Esparza-Gordillo J, Weidinger S, Fölster-Holst R, Bauerfeind Anja, et al , A common variant on chromosome 11q13 is associated with atopic dermatitis.. Nat Genet. 2009; 41:596-601.
Marenholz I, Kerscher T, Bauerfeind Anja, et al , An interaction between filaggrin mutations and early food sensitization improves the prediction of childhood asthma. J Allergy Clin Immunol. 2009; 123:911-6.
Bauerfeind Anja, Knoblauch H, Costanza MC, et al , Concordant association of lipid gene variation with a combined HDL/LDL-cholesterol phenotype in two European populations. Hum Hered. 2006; 61:123-31.
H Knoblauch, Bauerfeind Anja, et al , Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholestero. Hum Mol Genet . 2004; 13:993-1004.
Bauerfeind Anja, H Knoblauch, et al , Single nucleotide polymor¬phism haplotyes in the cholesteryl-ester transfer protein (CETP) gene and lipid phenotypes. Hum Hered. 2002; 54:166-173.
H Knoblauch, Bauerfeind Anja, et al , Common haplotypes in five genes influence genetic variance of LDL and HDL cholesterol in the general population. Hum Mol Genet. 2002; 11:1477-85.
Follman M, Heinemann Lothar A , Bauerfeind Anja, Garbe E, Treatment with potentially hepatotoxic drugs and the risk of hepatocellular carcinoma: results of a European case - control study. Pharmacoepidemiol Drug Saf . 2000; 9:417-22.
Strohmeyer D, Rössing C, Bauerfeind Anja, et al , Vascular en¬dothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate. 2000; 45:216-24.
Strohmeyer D, Rössing C, Strauss F, Bauerfeind Anja, et al , Treatment with potentially hepatotoxic drugs and the risk of hepatocellular carcinoma: results of a European case - control study. Prostate. 2000; 42:26-33.
Mantay K, Bauerfeind Anja, et al , Risk of serious hypoglycaemia and use of antihyper¬tensive drugs in a cohort of diabetic patients treated with insulin. Pharmacoepidemiol Drug Saf . 1999; 8(Suppl.2):257.
Mantay K, Bauerfeind Anja, et al , Antihypertensive drug treatment and the risk of severe hypoglycaemia in patients treated with oral antidiabetics. Pharmacoepidemiology and Drug Safety. 1999; 8(Suppl.2):258.

sidebar

Executive Team

  • Clare Barnett
  • Karl Pauls
  • Michael Schultze
  • Alfred Pauls
  • Anja Bauerfeind
  • Do Minh Thai
  • Elisabeth Finger
  • Jens A. Lange

Management Board

  • Klaas Heinemann
  • Clare Barnett
  • Marc Pignot
  • Karl Pauls
  • Johanna Poppe

Project Management Team

  • Pauline De Corte
  • Lisa Eggebrecht
  • Maria Cabral
  • Anitha Pitchika
  • Mohammed Dagher

Search

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Expertise

  • Real-World Evidence
  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Diagnostic tools
  • Data collection instruments

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2023 ZEG Berlin

Impressum

Website by Laura Yeffeth.